Skip to content

An Evaluation of an Injectable Material for Correction of Wrinkles

An Open Label Evaluation of the Safety and Efficacy of Calcium Hydroxylapatite (Radiesse®) Injection in the Correction of Jowl-Associated Chin Notches

Status
Withdrawn
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00510081
Enrollment
0
Registered
2007-08-01
Start date
2007-07-31
Completion date
2009-02-28
Last updated
2014-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Jowls

Brief summary

The objective of this study is to determine the effectiveness of a filler in improving wrinkles.

Detailed description

The primary objective of this study is to determine whether focal injection of calcium hydroxylapatite (Radiesse®), an injectable biodegradable filler, into jowl-induced chin notches can result in safe, aesthetically pleasing, and long-lasting correction of these.

Interventions

DEVICECalcium Hydroxylapatite injection

filler injection

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age 40-65 * Have wrinkles * The subjects are in good health. * The subject has willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator.

Exclusion criteria

* Subjects who have received within the past 3 months or are planning to receive in the next 6 months, botulinum toxin injections for correction of wrinkles. * Subjects who have received within the past one year any soft tissue augmentation material into the chin and experimental area (defined as any area on the face below the lower lip vermilion, excluding the lateral lip marionette line up to 1 cm below this level). * Subjects with prior history of nodule formation or hypersensitivity reactions to lidocaine or medium-term augmentation materials, including hyaluronic acid derivatives, poly-L-lactic acid, and calcium hydroxylapatite. * Subjects who are currently using anticoagulation therapy. * Subjects who have a history of bleeding disorders. * Subjects who are unable to understand the protocol or to give informed consent. * Subjects with mental illness.

Design outcomes

Primary

MeasureTime frame
Correction of wrinkles1 week

Secondary

MeasureTime frame
Development of adverse events1 week

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026